Incyte Corporation (INCY)
Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Why Incyte (INCY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Incyte (INCY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Incyte Corporation (INCY) Q1 2026 Earnings Call Transcript
Incyte Corporation (INCY) Q1 2026 Earnings Call Transcript
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Incyte (INCY) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.16 per share a year ago.
Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?
INCY heads into Q1 earnings with a $1.23 billion revenue view, driven by Jakafi, Opzelura, rising royalties and multiple new launches contributing to revenues.
Incyte Q1 Preview: The Growth Story Remains Intact
Incyte Corporation remains a Buy despite an 8% stock decline, with a widened undervaluation and a robust non-Jakafi growth story. INCY's aggressive reinvestment supports four major product launches in 2026–2027, aiming to offset Jakafi's 2028 patent cliff. Pipeline catalysts include Jakafi XR, Opzelura EU launch, Monjuvi in 1L DLBCL, and povorcitinib in HS, with management targeting $1B+ new franchise potential.
31,459 Shares in Incyte Corporation $INCY Bought by CPC Advisors LLC
CPC Advisors LLC bought a new position in shares of Incyte Corporation (NASDAQ: INCY) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 31,459 shares of the biopharmaceutical company's stock, valued at approximately $3,107,000. A number of other institutional investors
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Incyte (INCY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study
Incyte's povorcitinib shows sustained 54-week efficacy in HS, with strong response rates and safety profile, reinforcing its potential.
